Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Tianjin Pharmaceutical Da Ren Tang Group Corp stock

600329.SS
CNE000001808

Price

0
Today +/-
-0
Today %
-0 %

Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue, EBIT, Net Income

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Tianjin Pharmaceutical Da Ren Tang Group Corp, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Tianjin Pharmaceutical Da Ren Tang Group Corp from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Tianjin Pharmaceutical Da Ren Tang Group Corp’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Tianjin Pharmaceutical Da Ren Tang Group Corp. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Tianjin Pharmaceutical Da Ren Tang Group Corp’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Tianjin Pharmaceutical Da Ren Tang Group Corp’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Tianjin Pharmaceutical Da Ren Tang Group Corp’s growth potential.

Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue, EBIT and net profit per share

DateTianjin Pharmaceutical Da Ren Tang Group Corp RevenueTianjin Pharmaceutical Da Ren Tang Group Corp EBITTianjin Pharmaceutical Da Ren Tang Group Corp Net Income

Tianjin Pharmaceutical Da Ren Tang Group Corp stock margins

The Tianjin Pharmaceutical Da Ren Tang Group Corp margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Tianjin Pharmaceutical Da Ren Tang Group Corp. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Tianjin Pharmaceutical Da Ren Tang Group Corp.

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Tianjin Pharmaceutical Da Ren Tang Group Corp's sales revenue. A higher gross margin percentage indicates that the Tianjin Pharmaceutical Da Ren Tang Group Corp retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Tianjin Pharmaceutical Da Ren Tang Group Corp's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Tianjin Pharmaceutical Da Ren Tang Group Corp's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Tianjin Pharmaceutical Da Ren Tang Group Corp's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Tianjin Pharmaceutical Da Ren Tang Group Corp. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Tianjin Pharmaceutical Da Ren Tang Group Corp's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Tianjin Pharmaceutical Da Ren Tang Group Corp Margin History

Tianjin Pharmaceutical Da Ren Tang Group Corp Gross marginTianjin Pharmaceutical Da Ren Tang Group Corp Profit marginTianjin Pharmaceutical Da Ren Tang Group Corp EBIT marginTianjin Pharmaceutical Da Ren Tang Group Corp Profit margin

Tianjin Pharmaceutical Da Ren Tang Group Corp Stock Sales Revenue, EBIT, Earnings per Share

The Tianjin Pharmaceutical Da Ren Tang Group Corp earnings per share therefore indicates how much revenue Tianjin Pharmaceutical Da Ren Tang Group Corp has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tianjin Pharmaceutical Da Ren Tang Group Corp earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tianjin Pharmaceutical Da Ren Tang Group Corp's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tianjin Pharmaceutical Da Ren Tang Group Corp’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tianjin Pharmaceutical Da Ren Tang Group Corp's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue, EBIT and net profit per share

DateTianjin Pharmaceutical Da Ren Tang Group Corp Sales per ShareTianjin Pharmaceutical Da Ren Tang Group Corp EBIT per shareTianjin Pharmaceutical Da Ren Tang Group Corp Earnings per Share

Tianjin Pharmaceutical Da Ren Tang Group Corp business model

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is one of the leading pharmaceutical companies in China. It was founded in 1994 and is headquartered in the city of Tianjin in the northern part of the country. Zhongxin is a publicly traded company and employs over 6,000 employees. The business model of Zhongxin is diversified and includes manufacturing, research and development, sales, and marketing of pharmaceuticals and medical devices. The company strives to provide its customers with high-quality products and services and operates in various specialized areas. One of Zhongxin's main divisions is the manufacturing of pharmaceutical products. The company specializes in the production of cardiology, gastroenterology, oncology, and traditional Chinese medicines. Zhongxin operates multiple production facilities in China and has a productive R&D department focused on drug development. Another important part of Zhongxin's business is the distribution of its products. The company operates several distribution centers in China and is also increasing its presence in international markets. Distribution is done either directly to end customers or through intermediaries. In addition to the sale of medications, Zhongxin is also involved in medical wholesale activities, including retail and delivery of medical equipment and instruments. The company is capable of providing all types of medical devices and instruments from imaging and diagnostics to surgical instruments and implants. Zhongxin also has a specialized chemicals and raw materials division focused on the production of pharmaceutical active ingredients and intermediates. This gives the company additional control over the quality of its products as it is able to produce raw materials itself. The company is always seeking new innovations and heavily investing in research and development. In recent times, Zhongxin has invested in the development of biotech and nucleic acid therapies and intends to develop further innovative treatment methods. Zhongxin has also developed a strong presence in international markets in recent years. It has subsidiaries in several countries including the USA, Australia, Japan, and Europe. The company engages in joint ventures and strategic partnerships to enhance its raw material procurement and expand its reach internationally. Overall, Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a significant player in the pharmaceutical industry in China and on the international stage. The company has established a reputation as a reliable producer of high-quality medical products and services and continues to strive for success through innovation and expansion. Tianjin Pharmaceutical Da Ren Tang Group Corp is one of the most popular companies on Eulerpool.com.

Tianjin Pharmaceutical Da Ren Tang Group Corp SWOT Analysis

Strengths

Tianjin Zhongxin Pharmaceutical Group Corp Ltd possesses several strengths that contribute to its success:

  • Strong market presence: Tianjin Zhongxin Pharmaceutical Group Corp Ltd has established a solid position in the pharmaceutical industry, enabling it to enjoy a competitive advantage.
  • Diverse product portfolio: The company offers a wide range of pharmaceutical products, catering to various medical needs, which helps to mitigate the risk of relying on a single product or market segment.
  • Robust research and development (R&D) capabilities: Tianjin Zhongxin Pharmaceutical Group Corp Ltd invests significantly in R&D, allowing it to constantly innovate and develop new drugs to meet evolving market demands.
  • Strong brand reputation: The company has built a strong brand image over the years, which enhances customer trust and loyalty.

Weaknesses

Despite its strengths, Tianjin Zhongxin Pharmaceutical Group Corp Ltd also faces certain weaknesses:

  • Dependence on key markets: The company heavily relies on a few key markets for its revenue, leaving it vulnerable to economic and regulatory changes in those regions.
  • Challenges in international expansion: Tianjin Zhongxin Pharmaceutical Group Corp Ltd faces difficulties in expanding globally, due to variations in regulatory environments and market dynamics.
  • Limited brand recognition outside core markets: The company may struggle to gain recognition and market share in new markets where its brand is less known.

Opportunities

Tianjin Zhongxin Pharmaceutical Group Corp Ltd can leverage the following opportunities to grow its business:

  • Increasing demand for pharmaceutical products: The global healthcare sector is growing, presenting opportunities for the company to expand its product offerings and enter new markets.
  • Emerging markets: Expanding into emerging markets presents the potential for significant growth, as these regions experience increasing healthcare spending and demand for quality medicines.
  • Partnerships and collaborations: Forming strategic partnerships with other pharmaceutical companies or research institutions can enhance R&D capabilities and facilitate market access.

Threats

Tianjin Zhongxin Pharmaceutical Group Corp Ltd should be mindful of the following threats in the industry:

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous well-established players. Increased competition can impede market share growth and put downward pressure on pricing.
  • Stringent regulations: The company needs to comply with various regulations imposed by different countries, which can lead to delays and increased costs in the drug development and approval processes.
  • Intellectual property rights infringement: Protecting intellectual property rights is crucial in the pharmaceutical industry, as unauthorized copying or patent infringement can lead to revenue losses or legal disputes.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Tianjin Pharmaceutical Da Ren Tang Group Corp historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Tianjin Pharmaceutical Da Ren Tang Group Corp stock splits

In Tianjin Pharmaceutical Da Ren Tang Group Corp's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Tianjin Pharmaceutical Da Ren Tang Group Corp.

Tianjin Pharmaceutical Da Ren Tang Group Corp latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20140 0  (-41.49 %)2014 Q4
9/30/20140 0  (-56 %)2014 Q3
6/30/20140 0  (-14.19 %)2014 Q2
12/31/20130 0  (-24.56 %)2013 Q4
9/30/20130 0  (-57.57 %)2013 Q3
6/30/20130 0  (-20.82 %)2013 Q2
1

Eulerpool ESG Scorecard© for the Tianjin Pharmaceutical Da Ren Tang Group Corp stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

46

👫 Social

38

🏛️ Governance

81

Environment

Scope 1 - Direct Emissions
5,901.71
Scope 2 - Indirect emissions from purchased energy
31,489.237
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
37,390.947
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees32.236
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Tianjin Pharmaceutical Da Ren Tang Group Corp Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Citigroup Stock
Citigroup
SupplierCustomer0,69-0,040,800,660,430,57
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,36-0,43-0,80-0,59-0,420,31
Standard Chartered Stock
Standard Chartered
SupplierCustomer0,330,71-0,68-0,32-0,340,26
Tianjin Lisheng Pharm A Stock
Tianjin Lisheng Pharm A
SupplierCustomer0,120,910,830,280,17-0,40
Tianjin Development Hldgs Stock
Tianjin Development Hldgs
SupplierCustomer0,05-0,580,720,340,180,54
DBS Group Holdings Stock
DBS Group Holdings
SupplierCustomer-0,53-0,720,530,470,020,75
ABN AMRO DR Stock
ABN AMRO DR
SupplierCustomer-0,70-0,75-0,210,600,300,78
1

Most common questions regarding Tianjin Pharmaceutical Da Ren Tang Group Corp

What values and corporate philosophy does Tianjin Pharmaceutical Da Ren Tang Group Corp represent?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd represents values of innovation, integrity, and quality in the pharmaceutical industry. With a strong corporate philosophy focused on delivering cutting-edge healthcare solutions, the company strives to provide safe and effective pharmaceutical products to improve people's well-being. Tianjin Zhongxin Pharmaceutical Group Corp Ltd's commitment to research and development, along with its dedication to meeting international standards, has positioned the company as a leader in the global pharmaceutical market. Through its emphasis on quality control, continuous improvement, and customer satisfaction, Tianjin Zhongxin Pharmaceutical Group Corp Ltd ensures the delivery of reliable and trustworthy healthcare solutions.

In which countries and regions is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily present?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is primarily present in China.

What significant milestones has the company Tianjin Pharmaceutical Da Ren Tang Group Corp achieved?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd has achieved several significant milestones. It has successfully expanded its product portfolio, notably in the areas of cardiovascular, respiratory, and anti-infective medicines. The company has also secured numerous international certifications, including Good Manufacturing Practice (GMP) certification, ensuring the highest quality standards. Tianjin Zhongxin Pharmaceutical Group Corp Ltd has made remarkable strides in research and development as well, with several innovative drugs being registered and commercialized. Furthermore, the company has established a robust global presence by entering into strategic partnerships and expanding its market reach. These achievements consolidate Tianjin Zhongxin Pharmaceutical Group Corp Ltd's position as a leading player in the pharmaceutical industry.

What is the history and background of the company Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd, a leading pharmaceutical company, has a rich history and background. Established in [year], the company has been dedicated to providing high-quality healthcare products and services to global markets. With a focus on research and development, manufacturing, and marketing, Tianjin Zhongxin has emerged as a trusted name in the pharmaceutical industry. Its commitment to innovation, quality, and customer satisfaction has enabled it to expand its presence both domestically and internationally. Being one of the prominent players in the pharmaceutical market, Tianjin Zhongxin Pharmaceutical Group Corp Ltd continuously strives for excellence through its diverse product portfolio and relentless pursuit of breakthrough solutions in healthcare.

Who are the main competitors of Tianjin Pharmaceutical Da Ren Tang Group Corp in the market?

The main competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd in the market include other leading pharmaceutical companies such as Shanghai Pharmaceuticals Holding Co., Ltd., Sinopharm Group Co., Ltd., Fosun Pharma, and Jiangsu Hengrui Medicine Co., Ltd.

In which industries is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily active?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd primarily operates in the pharmaceutical industry.

What is the business model of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd focuses on the development, production, and sales of pharmaceutical products. As one of the leading pharmaceutical companies in China, Tianjin Zhongxin Pharmaceutical Group Corp Ltd aims to provide high-quality and affordable medications to improve the health and well-being of individuals. With a diverse product portfolio ranging from traditional Chinese medicine to modern pharmaceuticals, the company emphasizes research and innovation to meet the growing healthcare needs of its customers. By adhering to strict quality standards and maintaining a strong distribution network, Tianjin Zhongxin Pharmaceutical Group Corp Ltd ensures the availability and accessibility of its products nationwide.

What is the P/E ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

The P/E ratio cannot be calculated for Tianjin Pharmaceutical Da Ren Tang Group Corp at the moment.

What is the P/S ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

The P/S cannot be calculated for Tianjin Pharmaceutical Da Ren Tang Group Corp currently.

What is the Quality Investing of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The Quality Investing cannot be calculated for Tianjin Pharmaceutical Da Ren Tang Group Corp at the moment.

What is the revenue of Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

The revenue cannot currently be calculated for Tianjin Pharmaceutical Da Ren Tang Group Corp.

How high is the profit of Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

The profit cannot currently be calculated for Tianjin Pharmaceutical Da Ren Tang Group Corp.

What is the business model of Tianjin Pharmaceutical Da Ren Tang Group Corp

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a Chinese company specialized in the production and sale of pharmaceutical products, health and dietary supplements, and medical devices. Its business model is based on a comprehensive range of products and services that allow it to meet the needs of customers in different markets. The company is divided into several divisions, including the pharmaceutical products division, the dietary supplements division, and the medical devices division. Each of these divisions offers unique products and services tailored to specific needs and requirements. In the field of pharmaceutical products, Tianjin Zhongxin Pharmaceutical Group Corp Ltd manufactures a variety of drugs used to treat various diseases and conditions. This includes antibiotics, anti-inflammatory drugs, cancer medications, as well as treatments for cardiovascular diseases and diabetes. The company also has a research and development department that continuously works on the development of new drugs. The dietary supplements division offers a wide range of products aimed at improving health and well-being. These include vitamins, minerals, enzymes, and herbal extracts. The company adheres to strict standards in the production of its products and uses only high-quality and natural ingredients. The medical devices division of Tianjin Zhongxin Pharmaceutical Group Corp Ltd specializes in the production of medical devices such as blood glucose monitors and blood pressure monitors. These devices are of high quality and comply with all applicable standards and regulations. The business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd also includes collaborations with other companies and organizations around the world. The company has partnerships with a variety of domestic and international companies to expand its product range and strengthen its global presence. Overall, the business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd is focused on the development, production, and sale of high-quality pharmaceutical products, dietary supplements, and medical devices. Its divisions offer a wide range of products and services tailored to the needs of customers in different markets. Through its global presence and collaborations with other companies and organizations worldwide, the company ensures continuous expansion and future success.

What is the Tianjin Pharmaceutical Da Ren Tang Group Corp dividend?

Tianjin Pharmaceutical Da Ren Tang Group Corp pays a dividend of 0 CNY distributed over payouts per year.

How often does Tianjin Pharmaceutical Da Ren Tang Group Corp pay dividends?

The dividend cannot currently be calculated for Tianjin Pharmaceutical Da Ren Tang Group Corp or the company does not pay out a dividend.

What is the Tianjin Pharmaceutical Da Ren Tang Group Corp ISIN?

The ISIN of Tianjin Pharmaceutical Da Ren Tang Group Corp is CNE000001808.

What is the Tianjin Pharmaceutical Da Ren Tang Group Corp ticker?

The ticker of Tianjin Pharmaceutical Da Ren Tang Group Corp is 600329.SS.

All fundamentals about Tianjin Pharmaceutical Da Ren Tang Group Corp

Our stock analysis for Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.